IP Library › Granted Patent US 8,003,108
Granted Patent B2
US 8,003,108 · App. 11/410,540 · Granted Aug 23, 2011

Sclerostin epitopes

Assignees: Amgen Inc.; UCB SA
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,003,108
App. No.
11/410,540
Granted
Aug 23, 2011
Kind
B2
Abstract

Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

Claims (23)

1. A composition comprising a fragment of a polypeptide of SEQ ID NO:1, the fragment consisting of the amino acid sequence of SEQ ID NO:5.

2. A composition comprising a fragment of a polypeptide of SEQ ID NO:1, the fragment consisting of the amino acid sequence of SEQ ID NO:2.

3. A composition comprising two different fragments of a polypeptide of SEQ ID NO: 1, each fragment consisting of any one of the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5.

4. A composition comprising three different fragments of a polypeptide of SEQ ID NO: 1, each fragment consisting of any one of the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5.

5. A composition comprising four different fragments of a polypeptide of SEQ ID NO: 1, each fragment consisting of any one of the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5.

6. A composition comprising a fragment of a polypeptide of SEQ ID NO:1, the fragment consisting of the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, wherein SEQ ID NO:2 and 4 are joined by a disulfide bond at amino acid positions 57 and 111 with reference to SEQ ID NO:1, and SEQ ID NO:3 and 5 are joined by at least one of (a) a disulfide bond at amino acid positions 82 and 142 with reference to SEQ ID NO:1, and (b) a disulfide bond at amino acid positions 86 and 144 with reference to SEQ ID NO:1.

7. The composition of claim 5 or claim 6 wherein the fragment retains the tertiary structure of the corresponding polypeptide region of human sclerostin of SEQ ID NO:1.

8. The composition of claim 7 , wherein the fragment is produced by proteolytic digestion of the polypeptide of SEQ ID NO:1.

9. A composition comprising (a) a fragment consisting of 7 to 14 amino acids of SEQ ID NO:2, (b) a fragment consisting of 8 to 17 amino acids of SEQ ID NO:3, (c) a fragment consisting of 8 to 17 residues of SEQ ID NO:4, and (d) a fragment consisting of 6 to 12 amino acids of SEQ ID NO:5.

10. The composition of claim 9 , wherein the fragment consisting of 7 to 14 amino acids of SEQ ID NO:2 is attached to the fragment consisting of 8 to 17 residues of SEQ ID NO:4 by a disulfide bond, and the fragment consisting of 8 to 17 amino acids of SEQ ID NO:3 is attached to the fragment consisting of 6 to 12 residues of SEQ ID NO:5 by one or two disulfide bonds.

11. The composition of claim 10 , wherein

(a) the fragment consisting of 7 to 14 amino acids of SEQ ID NO:2 comprises amino acid position 57 with reference to SEQ ID NO: 1,

(b) the fragment consisting of 8 to 17 amino acids of SEQ ID NO:3 comprises amino acid position 82 and/or 86 with reference to SEQ ID NO: 1,

(c) the fragment consisting of 8 to 17 residues of SEQ ID NO:4 comprises amino acid position 111 with reference to SEQ ID NO: 1, and

(d) the fragment consisting of 6 to 12 amino acids of SEQ ID NO:5 comprises amino acid position 142 and/or 144 with reference to SEQ ID NO: 1,

wherein SEQ ID NO:2 and 4 are joined by a disulfide bond at amino acid positions 57 and 111 with reference to SEQ ID NO:1, and SEQ ID NO:3 and 5 are joined by at least one of (i) a disulfide bond at amino acid positions 82 and 142 with reference to SEQ ID NO:1, and (ii) a disulfide bond at amino acid positions 86 and 144 with reference to SEQ ID NO:1.

12. The composition of claim 9 , wherein

(a) the fragment consisting of 7 to 14 amino acids of SEQ ID NO:2 is SEQ ID NO:72,

(b) the fragment consisting of 8 to 17 amino acids of SEQ ID NO:3 is SEQ ID NO:70, and

(c) the fragment consisting of 6 to 12 amino acids of SEQ ID NO:5 is SEQ ID NO:71.

13. The composition of claim 9 , wherein the fragment retains the tertiary structure of the corresponding polypeptide region of human sclerostin of SEQ ID NO:1 and is produced by proteolytic digestion.

14. A composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO:70, a peptide consisting of the amino acid sequence of SEQ ID NO:71, a peptide consisting of the amino acid sequence of SEQ ID NO:72, and a peptide consisting of the amino acid sequence of SEQ ID NO:73, wherein SEQ ID NO:70 and SEQ ID NO:71 are joined by a disulfide bond, and SEQ ID NO:72 and SEQ ID NO:73 are joined by a disulfide bond.

15. The composition of claim 14 , wherein the fragment retains the tertiary structure of the corresponding polypeptide region of human sclerostin of SEQ ID NO:1 and is produced by proteolytic digestion.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2007
From: PASZTY, CHRISTOPHER J.; LU, HSIENG S.; HOFFMAN, KELLY S.; WINTERS, AARON G.
To: AMGEN INC.
Reel/Frame 018829/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2007
From: ROBINSON, MARTYN K.; HENRY, ALISTAIR; LATHAM, JOHN; LAWSON, ALISTAIR; WINKLER, DAVID
To: UCB SA
Reel/Frame 018829/0892 →
Continuity (5)
Provisional Application 60792645 · Apr 17, 2006
Provisional Application 60782244 · Mar 13, 2006
Provisional Application 60776847 · Feb 24, 2006
Provisional Application 60677583 · May 3, 2005
Related Publication 20070072797A1 · Mar 29, 2007